Ajanta Pharma Raises Profit 49% to 388 Crore Rupees in Second Quarter
Key Facts
Ajanta Pharma reported on October 30, 2026 that net profit after tax rose to 388 crore rupees in the second quarter of fiscal 2027, from 260 crore rupees a year earlier, an annual increase of 49%. The results covered the period ended September 30, 2026, as well as the first half of the fiscal year. Consolidated revenue from operations was 1,794 crore rupees, compared with 1,354 crore rupees in the second quarter of fiscal 2026, up 33%. Profit after tax accounted for 22% of revenue during the quarter, according to the company's official statement. Profit growth therefore outpaced revenue growth for the period, based on the figures disclosed by the company.
For the first half, revenue from operations rose to 3,420 crore rupees from 2,656 crore rupees in the comparable period, an increase of 29%. Net profit was 722 crore rupees, compared with 516 crore rupees, marking annual growth of 40%. The company said profit after tax as a share of revenue was 21% in the first half. The figures show revenue and profit continued to grow over the six months ended September 30, with the second quarter posting faster year-on-year growth in both revenue and net profit than the first-half rates. The company reported a return on capital employed of 41%, while return on net worth reached 31% in the first half.
Performance varied across the markets detailed in the disclosure. Revenue from branded generics in India was 504 crore rupees, compared with 432 crore rupees a year earlier, an increase of 16%. In the United States, generic drug revenue rose to 484 crore rupees from 344 crore rupees, up 41%. Branded drug sales in Africa were 312 crore rupees, up 41% from the comparable period. Institutional Africa revenue jumped to 116 crore rupees from 32 crore rupees, an increase of 259%. The results highlight differences among markets, with faster growth in the United States and institutional Africa than in India.
Ajanta Pharma said its brands in India outperformed the Indian pharmaceutical market's growth by 27 percentage points, according to IQVIA data for the twelve months ended September 2026. The company attributed the outperformance to new launches and volume growth. It said growth from new launches exceeded market growth by 70%, while volume growth exceeded market growth by 18%. The company linked its brands' outperformance in India to contributions from launches and volumes, while the disclosures did not attribute this performance to a single factor spanning the other markets. Quarterly data showed revenue growth in India was 16%, compared with 41% in the United States and Africa, according to the company's market classification.
In its U.S. pharmaceutical business, the company received 4 approvals and launched 3 products in the first half of fiscal 2027. It marketed a total of 52 products through abbreviated new drug applications by the end of the period. A further 17 applications were awaiting approval from the U.S. Food and Drug Administration. That figure places the pending applications alongside the approvals and launches recorded by the company during the same six months, without specifying expected decision dates. The company had scheduled its earnings call for October 30, 2026, between 16:00 and 17:00 India time, the day it announced its second-quarter and first-half results.